Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

NCT03371979 is registered in ClinicalTrials.gov with Aeglea Biotherapeutics as lead sponsor.

NCT NCT03371979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03371979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Lead sponsor
Aeglea Biotherapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
December 21, 2017
Completion date
January 1, 2021
Enrollment
68 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer